Sosei Heptares Eyes $3bn Sales From IBD Drug Returned By GSK

24 Nov 2023

The first-in-class, oral GPR35 agonist has shown preclinical promise as a potential treatment for gastrointestinal indications such as ulcerative colitis.

GSK plc may have decided against advancing an inflammatory bowel disease (IBD) candidate that was being developed with Sosei Heptares but the Japan-UK group believes it is getting back rights to a potential multi-billion dollar asset.

The Tokyo and Cambridge-based biotech is in talks with GSK to take back full ownership of GSK4381406, which it describes as a highly selective first-in-class, oral GPR35 agonist that the firms have been developing as a potential new treatment for IBD

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Multiple Launches Help Lilly’s Japan Growth

15 May 2025

• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

14 May 2025

• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.